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ABSTRACT 
Objective: Hypothyroid has still be a problem in Thailand. Lack of pharmacokinetics information of levothyroxine in athyreotic patients for modify dosing. 
Therefore, the aim of this study was to investigate the pharmacokinetic parameters of 2 doses of levothyroxine (50 µg and 100 µg) in such group of patients.  
Methods: The 24 athyreotic patients were recruited and randomly assigned to receive 50 µg or 100 µg of levothyroxine. The pharmacokinetic parameters 
(Cmax, Tmax, AUC0-8, ke, T1/2 and Vd) of FT4 and TSH were calculated by the non-compartment model. The parameters of 2 doses were compared.  
Results: From the results found that, by monitoring FT4, there was no statistically significant difference (p>0.05) of almost all pharmacokinetic 
parameters between 2 doses except Cmax which has significant greater in 100 µg of levothyroxine. While all pharmacokinetics parameters of TSH 
were not statistically significant difference. The use of non-compartment model seems appropriate for calculation of pharmacokinetic parameters of 
FT4 (R2 = 0.81) while it has poor predictive capacity in terms of TSH (R2 = 0.24).  
Conclusion: In conclusion, administration of 50 µg and 100 µg of levothyroxine to athyreotic patients have similar pharmacokinetic in term of FT4 
(non-significant different in Tmax, AUC) and TSH. Further study of these parameters in more subjects is needed.  
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INTRODUCTION 
Hypothyroid is the condition that mostly found in athyreotic patients. 
The incidence of low free T4 (FT4) and high Thyroid Stimulating 
Hormone (TSH) is about 0.3% while the incidence of low thyroid 
hormone is found to 4.3% [1-3] The general treatment of hypothyroid 
should gradually modified drug dosing. American Association of 
Clinical Endocrinologists recommended Levothyroxine (L-T4) 1.6 
mcg/kg/day by begin with 12.5 mcg/day and then increase dose 
gradually depends on age, weight, cardiovascular status and duration 
of hypothyroid [4-5].  
In Thailand, the endocrine specialist recommended high dose oral 
levothyroxine 1000 µg for a single dose. Currently, there have not 
been studied of efficacy and side effects of high doses regimen.  
However, there are several studies in high doses of levothyroxine in 
patients with hypothyroid [6-7], the study found that myxedema 
coma or myxedema ileus, Levothyroxine oral route has variable 
absorption, but patients had a better response after administration. 
Intravenous levothyroxine can make a higher level of thyroid 
hormone. However, it cannot conclude that, which appropriate dose 
should be administered in severe hypothyroidism.  
Vicky Blakesley et al.8reported Bioequivalence of Levothyroxine oral 
400, 450 and 600 µg in healthy volunteer and measured thyroid 
hormone to determine Cmax (maximum serum concentration), time to 
Cmax, and AUC (area under the serum concentration-time curve) and 
suggested that the bioequivalence study of levothyroxine should use 
endogenous T4 in the calculation, and the serious adverse effects were 
not found in high-dose levothyroxine. In Thailand, there is a lack of 
pharmacokinetic information of levothyroxine pharmacokinetics in 
hypothyroid patients. Therefore, this study aimed to investigate the 
pharmacokinetic parameters of 2 doses levothyroxine in such patients.  
MATERIALS AND METHODS  
Patients 
Twenty-four primary hypothyroidism patients with underlying well-
differentiated thyroid cancer were recruited. Patients had a Total or 
Near-total thyroidectomy and stop levothyroxine for 6 w and had 
131I radiation therapy which is available as standard treatment.  
Inclusion criteria 
1. Males or females whose ages between 15-60 y old 
2. TSH>30mIU/ml  
3. No underlying diseases such as Cardiovascular diseases, Liver 
insufficiency (AST and/or ALT>3 times UL), renal insufficiency 
(Scr>1.5 mg/dL) 
4. No receiving other drugs that affect levothyroxine absorption 
such as calcium-containing drugs, anticonvulsants, oestrogens, and 
proton pump inhibitors or H2 blockers. 
Exclusion criteria  
Patients were excluded if they 
1. Were poor compliance with drug regimens  
2. Were pregnancy or lactation 
3. Had hypersensitivity or intolerate to thyroxine 
4. Had infectious or liver diseases  
5. Were considered by the physician as inappropriate to be 
included in this study. 
Drug administration 
Patients were administered levothyroxine 50 µg (50µg) 1 tablets or 
Levothyroxine 100 µg (50µg 2 tablets) single dose.  
Pharmacokinetic study 
Pharmacokinetic analysis 
Levothyroxine plasma concentrations were analysed as a function of 
time and the following pharmacokinetic parameters were obtained 
for each subject; the maximum plasma concentration (Cmax), Area 
under the concentration versus time curve for 8 h (AUC0-8), 
Elimination rate constant (ke), and volume of distribution (Vd). All 
pharmacokinetic parameters of free T4 (FT4) and Thyroid 
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Stimulation hormone (TSH) were assessed by Win-nonlin 
professional software (version1, Pharsight corporation, Pato 
Alta,California) and non-compartment methods were used.  
Data analysis 
Student t-test statistic was used to test the different of 
pharmacokinetic parameters between 2 groups of different 
regimens. The statistically significant difference was considered 
when p value was less than 0.05.  
RESULTS 
The pharmacokinetic parameters that found in 24 hypothyroid 
subjects were presented in table 1 and table 2 respectively 
 
Table 1: Pharmacokinetics parameters of FT4 in 24 hypothyroid subjects 
Pharmacokinetic parameters (Mean+SD) L-thyroxine 50(µg) n=12 L-thyroxine 100(µg) n=12 P value* 
Cmax (ng/ml) 0.25+0.06 0.46+0.29 0.027 
Tmax (h)** 3+0.4 2.92+0.45 0.83 
AUC 0-8 (ng/dL*h) 1.93+1.41 3.18+2.31 0.101 
Ke (h-1)*** 0.03+0.02 0.02+0.01 0.24 
CL (mL/min)*** 5.72+5.27 5.52+2.34 0.88 
T1/2 (h)*** 32.14+22.61 39.70+18.72 0.74 
Vd (L)*** 205.36+76.34 266.0+43.13 0.057 
*between Thyroxine group, **n=4 for Thyroxine 100 (µg) n=3 for Thyroxine 50 (µg), ***n=10 for Thyroxine 100 (µg) n=11 for Thyroxine 50 (µg), 
Average R2= 0.81 
 
Table 2: Pharmacokinetics parameters of TSH in 24 hypothyroid subjects 
Pharmacokinetic parameters (Mean+SD) L-thyroxine 50(µg) n=12 L-thyroxine 100(µg) n=12 P value* 
Cmax (ng/ml) 163.5+114.3 142.14+56.37 0.48 
Tmax (h)** 2.3+1.5 4.3+3.3 NA 
AUC 0-8 (ng/dL*h) 995.53+405.14 1166.3+764.1 0.42 
Ke (h-1)*** 0.019+0.017 0.02+0.01 0.36 
CL (mL/min)*** 0.0046+0.003 0.0025+0.035 0.28 
T1/2 (h)*** 107.20+103.94 90.24+118.52 0.74 
Vd (L)*** 0.406+0.23 1.015+0.869 0.057 
*between Thyroxine group, **n=10 for Thyroxine 100 (µg) n=11 for Thyroxine 50 (µg), ***n=9 for Thyroxine 100 (µg) n=11 for Thyroxine 50 (µg), 
Average R2= 0.24 
 
DISCUSSION 
According to the results, the pharmacokinetic parameters of 
levothyroxine 50 µg and 100 µg which measure by monitor FT4 have 
not significant difference except peak concentration (Cmax) is higher 
in levothyroxine 100 µg, while all pharmacokinetic parameters in 
terms of TSH were not significant difference. It seems that may be the 
pharmacokinetic of levothyroxine may have non-linear behaviour.  
When comparison of these parameters with the previous study 
found that, the tmax and average half-life were similar to this 
study.[9-11] The much variations is Cmax and AUC when compare to 
previous studies since due to the hypothyroid status of patients in 
this study which may had lower T4 baseline and 50-100 µg single 
dose cannot make FT4 reach for normal range and it implied that 
non-compartmental method could be used in calculation of 
pharmacokinetic parameters of LT4 with good R 2 (average = 0.8), 
while is not appropriate use for TSH because R 2 is quite low 
(average =0.2). Moreover, the sensitivity of TSH is less than FT4.  
This study leads to persuaded establishing the use of the 
pharmacokinetic model for monitoring FT4 in athreotic patients 
which is useful in levothyroxine dose adjustment.  
However, this study had some limitations, because of a small 
number of subjects, the pharmacokinetics parameters may be not 
generalised for every patient, further study with more number of 
subjects are needed. The second point is there is no repeated study 
for application of this model to another group of patients for proving 
about the accuracy of the model. Using this model for levothyroxine 
dose adjustment in another group of athyreotic patients for 
measuring the accuracy may help to prove about the generalization 
of this proposed model.  
CONCLUSION 
In conclusion, administration of levothyroxine (50 µg) and 
levothyroxine (100 µg) have similar pharmacokinetic in term of FT4 
(non-significant different in Tmax, AUC) and TSH. Further study of 
these parameters in more subjects is needed.  
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